RT Journal Article
SR Electronic
T1 Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Ovary
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP S20
OP S25
DO 10.1097/IGC.0000000000000289
VO 24
IS Supp 3
A1 Okamoto, Aikou
A1 Glasspool, Rosalind M.
A1 Mabuchi, Seiji
A1 Matsumura, Noriomi
A1 Nomura, Hiroyuki
A1 Itamochi, Hiroaki
A1 Takano, Masashi
A1 Takano, Tadao
A1 Susumu, Nobuyuki
A1 Aoki, Daisuke
A1 Konishi, Ikuo
A1 Covens, Alan
A1 Ledermann, Jonathan
A1 Mezzazanica, Delia
A1 Steer, Christopher
A1 Millan, David
A1 McNeish, Iain A.
A1 Pfisterer, Jacobus
A1 Kang, Sokbom
A1 Gladieff, Laurence
A1 Bryce, Jane
A1 Oza, Amit
YR 2014
UL http://ijgc.bmj.com/content/24/Supp_3/S20.abstract
AB Abstract Clear cell carcinoma of the ovary (CCC) is a histologic subtype of epithelial ovarian cancer with a distinct clinical behavior. There are marked geographic differences in the prevalence of CCC. The CCC is more likely to be detected at an early stage than high-grade serous cancers, and when confined within the ovary, the prognosis is good. However, advanced disease is associated with a very poor prognosis and resistance to standard treatment. Cytoreductive surgery should be performed for patients with stage II, III, or IV disease. An international phase III study to compare irinotecan/cisplatin and paclitaxel/carboplatin as adjuvant chemotherapy for stage IIV CCC has completed enrollment (GCIG/JGOG3017). Considering the frequent PIK3CA mutation in CCC, dual inhibitors targeting PI3K, AKT in the mTOR pathway, are promising. Performing these trials and generating the evidence will require considerable international collaboration.